Synergy CHC（SNYR）株式概要シナジーCHCコーポレーションは、米国、カナダ、メキシコ、そして国際的に消費者向けヘルスケア、美容、ライフスタイル製品を提供している。 詳細SNYR ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長5/6過去の実績0/6財務の健全性0/6配当金0/6報酬当社が推定した公正価値より92.2%で取引されている 収益は年間150.66%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $4M )US市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るSNYR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN96.5% undervaluedAnalystHighTarget•3mo agoRapid Retail Expansion And Direct Store Distribution Will Transform Long Term Earnings Power1200AN95.9% undervaluedAnalystConsensusTarget•3mo agoBrain Health And Clean Energy Trends Will Support Long Term Undervaluation Thesis601AN95.1% undervaluedAnalystLowTarget•2mo agoCautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins Ahead600Top Analyst NarrativesAN96.5% undervaluedAnalystHighTarget•3mo agoRapid Retail Expansion And Direct Store Distribution Will Transform Long Term Earnings Power1200AN95.9% undervaluedAnalystConsensusTarget•3mo agoBrain Health And Clean Energy Trends Will Support Long Term Undervaluation Thesis601AN95.1% undervaluedAnalystLowTarget•2mo agoCautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins Ahead600View all narrativesSynergy CHC Corp. 競合他社CyanotechSymbol: OTCPK:CYANMarket cap: US$3.8mCCA IndustriesSymbol: OTCPK:CAWWMarket cap: US$3.6mCV SciencesSymbol: OTCPK:CVSIMarket cap: US$5.8mIntegrated BioPharmaSymbol: OTCPK:INBPMarket cap: US$6.9m価格と性能株価の高値、安値、推移の概要Synergy CHC過去の株価現在の株価US$0.2552週高値US$4.0052週安値US$0.24ベータ0.781ヶ月の変化-51.79%3ヶ月変化-84.44%1年変化-88.30%3年間の変化-17.38%5年間の変化-33.37%IPOからの変化-98.97%最新ニュースお知らせ • May 18Synergy CHC Corp. Announces Notice Of Non-Compliance With Minimum Bid Price Requirement From NasdaqSynergy CHC Corp. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to November 11, 2026. If the Company does not regain compliance by November 11, 2026, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with other applicable Nasdaq listing requirements.お知らせ • Apr 21Synergy CHC Corp., Annual General Meeting, Jun 29, 2026Synergy CHC Corp., Annual General Meeting, Jun 29, 2026.お知らせ • Apr 02Synergy CHC Corp. announced delayed annual 10-K filingOn 04/01/2026, Synergy CHC Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Mar 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$8.3m). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (7.5% net profit margin). Market cap is less than US$100m (US$13.6m market cap).お知らせ • Mar 18Synergy CHC Corp. to Report Q4, 2025 Results on Mar 31, 2026Synergy CHC Corp. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2026新しいナラティブ • Mar 05Cautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins AheadCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?最新情報をもっと見るRecent updatesお知らせ • May 18Synergy CHC Corp. Announces Notice Of Non-Compliance With Minimum Bid Price Requirement From NasdaqSynergy CHC Corp. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to November 11, 2026. If the Company does not regain compliance by November 11, 2026, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with other applicable Nasdaq listing requirements.お知らせ • Apr 21Synergy CHC Corp., Annual General Meeting, Jun 29, 2026Synergy CHC Corp., Annual General Meeting, Jun 29, 2026.お知らせ • Apr 02Synergy CHC Corp. announced delayed annual 10-K filingOn 04/01/2026, Synergy CHC Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Mar 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$8.3m). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (7.5% net profit margin). Market cap is less than US$100m (US$13.6m market cap).お知らせ • Mar 18Synergy CHC Corp. to Report Q4, 2025 Results on Mar 31, 2026Synergy CHC Corp. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2026新しいナラティブ • Mar 05Cautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins AheadCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?お知らせ • Feb 27Synergy CHC Corp. announced that it expects to receive $31.3 million in fundingSynergy CHC Corp. announced a private placement of Common Shares of the company to raise gross proceeds of $31,300,000 on February 27, 2026.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.30, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 337% over the past three years.新しいナラティブ • Feb 17Brain Health And Clean Energy Trends Will Support Long Term Undervaluation ThesisCatalysts About Synergy CHC Synergy CHC develops and sells FOCUSfactor branded brain health supplements and functional beverages across retail, convenience and international channels. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Feb 03Rapid Retail Expansion And Direct Store Distribution Will Transform Long Term Earnings PowerCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional energy and brain health beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?分析記事 • Jan 28Investors Aren't Buying Synergy CHC Corp.'s (NASDAQ:SNYR) EarningsWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...お知らせ • Dec 17Synergy CHC Corp. Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico &Latin AmericaSynergy CHC Corp. announced that Pedro Colmenares has been appointed Director of Sales &Marketing for Mexico &Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. As Director of Sales and Marketing for Mexico and Latin America, he will play a central role in executing this strategy and driving growth across both the Companys supplement and functional beverage portfolios, building a scalable commercial foundation to support long-term growth. Mr. Colmenares is a senior commercial executive with over 18 years of experience across the pharmaceutical, nutraceutical, OTC, and consumer health sectors. He has successfully led market entry and expansion initiatives throughout Mexico and Latin America, consistently transforming underdeveloped markets into high-performing, sustainable businesses. His background includes leadership roles at Procter &Gamble and Victus/Megalabs, where he built scaled regional sales, marketing, and distribution platforms through strategic partnerships and omnichannel execution. Throughout his career, Mr. Colmenares has launched and developed operations in multiple countries across Latin America, driving accelerated growth through disciplined go-to-market strategies, localized brand development, and strong retailer and supplier relationships. His experience spans both multinational and regional organizations, providing a deep understanding of the operational and cultural dynamics required to scale consumer health brands in the region.Valuation Update With 7 Day Price Move • Dec 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.84, the stock trades at a trailing P/E ratio of 8x. Average forward P/E is 14x in the Personal Products industry in the US. Total loss to shareholders of 65% over the past year.お知らせ • Nov 27Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million.Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering分析記事 • Nov 20Should You Think About Buying Synergy CHC Corp. (NASDAQ:SNYR) Now?Synergy CHC Corp. ( NASDAQ:SNYR ), is not the largest company out there, but it saw a decent share price growth of 18...Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.012 (vs US$0.10 in 3Q 2024)Third quarter 2025 results: EPS: US$0.012 (down from US$0.10 in 3Q 2024). Revenue: US$8.01m (up 12% from 3Q 2024). Net income: US$125.3k (down 84% from 3Q 2024). Profit margin: 1.6% (down from 11% in 3Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in the US.お知らせ • Oct 31Synergy CHC Corp. to Report Q3, 2025 Results on Nov 13, 2025Synergy CHC Corp. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$2.69, the stock trades at a trailing P/E ratio of 9.3x. Average forward P/E is 15x in the Personal Products industry in the US.Board Change • Sep 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Nitin Kaushal was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 23Synergy CHC Corp. Announces Management AppointmentsSynergy CHC Corp. announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company’s expansion in functional beverages, and Teresa Thompson has been appointed to Synergy’s Board of Directors (the “Board”), effective immediately. In connection with Woodburn’s new role, he has resigned from the Board. Thompson will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, filling the positions previously held by Woodburn.Scott Woodburn, who has served on Synergy’s Board since October 2024, brings over 30 years of executive leadership across the global beverage and consumer goods industries. A former Vice President of National and Global Accounts at Coca-Cola, he has led international brand growth, executed large-scale sales strategies, and built enduring partnerships with major retail and QSR chains. He also leads a beverage-focused consulting firm, serves as an advisor to investment bank Silverwood Partners, and most recently held the role of SVP of Sales at Fuling USA. With a proven track record scaling Fortune 500 brands, Woodburn is set to accelerate Synergy’s beverage innovation and market expansion in the rapidly growing $100B+ global energy and wellness drinks market. Synergy has appointed Teresa Thompson to its Board of Directors, filling the vacancy created by Woodburn’s transition. Thompson is a seasoned retail executive with nearly four decades of experience at Costco Wholesale, including 29 years as a Pharmacy OTC Buyer. In that role, she oversaw the vitamins and supplements categories for Costco’s U.S. warehouses, managing vendor relationships, optimizing product assortments, and implementing strategic initiatives that enhanced the customer experience.Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$2.56, the stock trades at a trailing P/E ratio of 8.8x. Average forward P/E is 15x in the Personal Products industry in the US. Total returns to shareholders of 7.6% over the past year.New Risk • Aug 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$12m). High level of non-cash earnings (84% accrual ratio). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$23.4m market cap).分析記事 • Aug 27Synergy CHC's (NASDAQ:SNYR) Problems Go Beyond Poor ProfitSynergy CHC Corp.'s ( NASDAQ:SNYR ) lackluster earnings announcement last week disappointed investors. We think that...お知らせ • Aug 26Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million.Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,750,000 Price\Range: $2.5 Discount Per Security: $0.175Valuation Update With 7 Day Price Move • Aug 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to US$2.90, the stock trades at a trailing P/E ratio of 8.5x. Average forward P/E is 16x in the Personal Products industry in the US.お知らせ • Aug 16Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million.Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,275,510 Price\Range: $3.92Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: US$0.17 (vs US$0.087 in 2Q 2024)Second quarter 2025 results: EPS: US$0.17 (up from US$0.087 in 2Q 2024). Revenue: US$8.13m (up 1.4% from 2Q 2024). Net income: US$1.47m (up 125% from 2Q 2024). Profit margin: 18% (up from 8.2% in 2Q 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in the US.Recent Insider Transactions • Aug 03CEO & Chairman recently bought US$80k worth of stockOn the 30th of July, Jack Ross bought around 28k shares on-market at roughly US$2.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jack has been a buyer over the last 12 months, purchasing a net total of US$2.9m worth in shares.お知らせ • Aug 01Synergy CHC Corp. to Report Q2, 2025 Results on Aug 14, 2025Synergy CHC Corp. announced that they will report Q2, 2025 results Pre-Market on Aug 14, 2025Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$3.61, the stock trades at a trailing P/E ratio of 13.4x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 203% over the past year.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 33%After last week's 33% share price gain to US$3.24, the stock trades at a trailing P/E ratio of 12.1x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 4,850% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 27%After last week's 27% share price gain to US$2.65, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 3,949% over the past three years.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$2.07, the stock trades at a trailing P/E ratio of 7.7x. Average forward P/E is 23x in the Personal Products industry in the US. Total returns to shareholders of 3,063% over the past three years.New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$16m). High level of non-cash earnings (83% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (7.2% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$17.7m market cap).Reported Earnings • May 15First quarter 2025 earnings released: EPS: US$0.10 (vs US$0.077 in 1Q 2024)First quarter 2025 results: EPS: US$0.10 (up from US$0.077 in 1Q 2024). Revenue: US$8.17m (down 13% from 1Q 2024). Net income: US$876.3k (up 51% from 1Q 2024). Profit margin: 11% (up from 6.2% in 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Personal Products industry in the US.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$1.77, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 2,875% over the past three years.お知らせ • May 02Synergy CHC Corp. to Report Q1, 2025 Results on May 15, 2025Synergy CHC Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025お知らせ • Apr 19Synergy CHC Corp., Annual General Meeting, Jun 18, 2025Synergy CHC Corp., Annual General Meeting, Jun 18, 2025.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 40%After last week's 40% share price gain to US$2.50, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 16x in the Personal Products industry in the US. Total returns to shareholders of 6,903% over the past three years.New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$17m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.1% net profit margin). Market cap is less than US$100m (US$19.7m market cap).Reported Earnings • Mar 31Full year 2024 earnings released: EPS: US$0.28 (vs US$0.84 in FY 2023)Full year 2024 results: EPS: US$0.28 (down from US$0.84 in FY 2023). Revenue: US$34.8m (down 19% from FY 2023). Net income: US$2.12m (down 67% from FY 2023). Profit margin: 6.1% (down from 15% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the US.Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Personal Products industry in the US. Total returns to shareholders of 12,589% over the past three years.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 21x in the Personal Products industry in the US. Total returns to shareholders of 22,971% over the past three years.Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$4.15, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 26x in the Personal Products industry in the US. Total returns to shareholders of 31,604% over the past three years.お知らせ • Nov 27Synergy CHC Corp. to Report Q3, 2024 Results on Dec 06, 2024Synergy CHC Corp. announced that they will report Q3, 2024 results Pre-Market on Dec 06, 2024お知らせ • Oct 25Synergy CHC Corp. Common Stock Deleted from OTC EquitySynergy CHC Corp. Common Stock has been deleted from OTC Equity effective October 23, 2024, due to Market Center Change Listed on NASDAQ.お知らせ • Oct 23Synergy CHC Corp. has completed an IPO in the amount of $10.35 million.Synergy CHC Corp. has completed an IPO in the amount of $10.35 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,150,000 Price\Range: $9 Discount Per Security: $0.63お知らせ • Jun 28Synergy CHC Corp. has filed an IPO in the amount of $23 million.Synergy CHC Corp. has filed an IPO in the amount of $23 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: New Market Listingお知らせ • Jul 18Synergy CHC Files Form 15Synergy CHC Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock, par value $0.00001 per share.株主還元SNYRUS Personal ProductsUS 市場7D-18.1%-2.1%-0.3%1Y-88.3%-20.0%26.7%株主還元を見る業界別リターン: SNYR過去 1 年間で-20 % の収益を上げたUS Personal Products業界を下回りました。リターン対市場: SNYRは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。価格変動Is SNYR's price volatile compared to industry and market?SNYR volatilitySNYR Average Weekly Movement13.9%Personal Products Industry Average Movement7.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: SNYRの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SNYRの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201028Jack Rosssynergychc.comシナジーCHC社は、米国、カナダ、メキシコ、および海外で、消費者向けヘルスケア、美容、ライフスタイル製品を提供している。FOCUSfactorのブランド名で脳の健康栄養サプリメントを、Flat Tummyのブランド名でお茶、シェイク、ロリポップ、サプリメント、アパレル、エクササイズアクセサリーなどのライフスタイルとウェルネス製品とアクセサリーを提供している。また、Hand MDのブランド名でハンドケア製品、ホメオパシー製品のNeuragen、市販薬のUrgentRxも提供している。同社は、クラブ、量販店、その他の小売店を通じて製品を販売している。以前はシナジーストリップス社として知られていたが、2015年8月にシナジーCHC社に社名変更した。同社は2010年に法人化され、メイン州ウィンダムに本社を置いている。もっと見るSynergy CHC Corp. 基礎のまとめSynergy CHC の収益と売上を時価総額と比較するとどうか。SNYR 基礎統計学時価総額US$3.86m収益（TTM）-US$15.79m売上高(TTM)US$27.70m0.1xP/Sレシオ-0.2xPER（株価収益率SNYR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SNYR 損益計算書（TTM）収益US$27.70m売上原価US$9.59m売上総利益US$18.11mその他の費用US$33.90m収益-US$15.79m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.06グロス・マージン65.37%純利益率-56.98%有利子負債／自己資本比率-109.2%SNYR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 14:54終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synergy CHC Corp. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Edward WooAscendiant Capital Markets LLCSean McGowanRoth Capital Partners
お知らせ • May 18Synergy CHC Corp. Announces Notice Of Non-Compliance With Minimum Bid Price Requirement From NasdaqSynergy CHC Corp. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to November 11, 2026. If the Company does not regain compliance by November 11, 2026, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with other applicable Nasdaq listing requirements.
お知らせ • Apr 21Synergy CHC Corp., Annual General Meeting, Jun 29, 2026Synergy CHC Corp., Annual General Meeting, Jun 29, 2026.
お知らせ • Apr 02Synergy CHC Corp. announced delayed annual 10-K filingOn 04/01/2026, Synergy CHC Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Mar 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$8.3m). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (7.5% net profit margin). Market cap is less than US$100m (US$13.6m market cap).
お知らせ • Mar 18Synergy CHC Corp. to Report Q4, 2025 Results on Mar 31, 2026Synergy CHC Corp. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2026
新しいナラティブ • Mar 05Cautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins AheadCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?
お知らせ • May 18Synergy CHC Corp. Announces Notice Of Non-Compliance With Minimum Bid Price Requirement From NasdaqSynergy CHC Corp. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to November 11, 2026. If the Company does not regain compliance by November 11, 2026, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with other applicable Nasdaq listing requirements.
お知らせ • Apr 21Synergy CHC Corp., Annual General Meeting, Jun 29, 2026Synergy CHC Corp., Annual General Meeting, Jun 29, 2026.
お知らせ • Apr 02Synergy CHC Corp. announced delayed annual 10-K filingOn 04/01/2026, Synergy CHC Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Mar 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$8.3m). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (7.5% net profit margin). Market cap is less than US$100m (US$13.6m market cap).
お知らせ • Mar 18Synergy CHC Corp. to Report Q4, 2025 Results on Mar 31, 2026Synergy CHC Corp. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2026
新しいナラティブ • Mar 05Cautious On Beverage Rollout And DSD Costs Yet Expecting Healthier Margins AheadCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?
お知らせ • Feb 27Synergy CHC Corp. announced that it expects to receive $31.3 million in fundingSynergy CHC Corp. announced a private placement of Common Shares of the company to raise gross proceeds of $31,300,000 on February 27, 2026.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$1.30, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 337% over the past three years.
新しいナラティブ • Feb 17Brain Health And Clean Energy Trends Will Support Long Term Undervaluation ThesisCatalysts About Synergy CHC Synergy CHC develops and sells FOCUSfactor branded brain health supplements and functional beverages across retail, convenience and international channels. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Feb 03Rapid Retail Expansion And Direct Store Distribution Will Transform Long Term Earnings PowerCatalysts About Synergy CHC Synergy CHC develops and markets FOCUSfactor branded cognitive health supplements and functional energy and brain health beverages across retail and international channels. What are the underlying business or industry changes driving this perspective?
分析記事 • Jan 28Investors Aren't Buying Synergy CHC Corp.'s (NASDAQ:SNYR) EarningsWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...
お知らせ • Dec 17Synergy CHC Corp. Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico &Latin AmericaSynergy CHC Corp. announced that Pedro Colmenares has been appointed Director of Sales &Marketing for Mexico &Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. As Director of Sales and Marketing for Mexico and Latin America, he will play a central role in executing this strategy and driving growth across both the Companys supplement and functional beverage portfolios, building a scalable commercial foundation to support long-term growth. Mr. Colmenares is a senior commercial executive with over 18 years of experience across the pharmaceutical, nutraceutical, OTC, and consumer health sectors. He has successfully led market entry and expansion initiatives throughout Mexico and Latin America, consistently transforming underdeveloped markets into high-performing, sustainable businesses. His background includes leadership roles at Procter &Gamble and Victus/Megalabs, where he built scaled regional sales, marketing, and distribution platforms through strategic partnerships and omnichannel execution. Throughout his career, Mr. Colmenares has launched and developed operations in multiple countries across Latin America, driving accelerated growth through disciplined go-to-market strategies, localized brand development, and strong retailer and supplier relationships. His experience spans both multinational and regional organizations, providing a deep understanding of the operational and cultural dynamics required to scale consumer health brands in the region.
Valuation Update With 7 Day Price Move • Dec 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.84, the stock trades at a trailing P/E ratio of 8x. Average forward P/E is 14x in the Personal Products industry in the US. Total loss to shareholders of 65% over the past year.
お知らせ • Nov 27Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million.Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
分析記事 • Nov 20Should You Think About Buying Synergy CHC Corp. (NASDAQ:SNYR) Now?Synergy CHC Corp. ( NASDAQ:SNYR ), is not the largest company out there, but it saw a decent share price growth of 18...
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.012 (vs US$0.10 in 3Q 2024)Third quarter 2025 results: EPS: US$0.012 (down from US$0.10 in 3Q 2024). Revenue: US$8.01m (up 12% from 3Q 2024). Net income: US$125.3k (down 84% from 3Q 2024). Profit margin: 1.6% (down from 11% in 3Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in the US.
お知らせ • Oct 31Synergy CHC Corp. to Report Q3, 2025 Results on Nov 13, 2025Synergy CHC Corp. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to US$2.69, the stock trades at a trailing P/E ratio of 9.3x. Average forward P/E is 15x in the Personal Products industry in the US.
Board Change • Sep 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Nitin Kaushal was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 23Synergy CHC Corp. Announces Management AppointmentsSynergy CHC Corp. announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company’s expansion in functional beverages, and Teresa Thompson has been appointed to Synergy’s Board of Directors (the “Board”), effective immediately. In connection with Woodburn’s new role, he has resigned from the Board. Thompson will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, filling the positions previously held by Woodburn.Scott Woodburn, who has served on Synergy’s Board since October 2024, brings over 30 years of executive leadership across the global beverage and consumer goods industries. A former Vice President of National and Global Accounts at Coca-Cola, he has led international brand growth, executed large-scale sales strategies, and built enduring partnerships with major retail and QSR chains. He also leads a beverage-focused consulting firm, serves as an advisor to investment bank Silverwood Partners, and most recently held the role of SVP of Sales at Fuling USA. With a proven track record scaling Fortune 500 brands, Woodburn is set to accelerate Synergy’s beverage innovation and market expansion in the rapidly growing $100B+ global energy and wellness drinks market. Synergy has appointed Teresa Thompson to its Board of Directors, filling the vacancy created by Woodburn’s transition. Thompson is a seasoned retail executive with nearly four decades of experience at Costco Wholesale, including 29 years as a Pharmacy OTC Buyer. In that role, she oversaw the vitamins and supplements categories for Costco’s U.S. warehouses, managing vendor relationships, optimizing product assortments, and implementing strategic initiatives that enhanced the customer experience.
Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$2.56, the stock trades at a trailing P/E ratio of 8.8x. Average forward P/E is 15x in the Personal Products industry in the US. Total returns to shareholders of 7.6% over the past year.
New Risk • Aug 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$12m). High level of non-cash earnings (84% accrual ratio). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$23.4m market cap).
分析記事 • Aug 27Synergy CHC's (NASDAQ:SNYR) Problems Go Beyond Poor ProfitSynergy CHC Corp.'s ( NASDAQ:SNYR ) lackluster earnings announcement last week disappointed investors. We think that...
お知らせ • Aug 26Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million.Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,750,000 Price\Range: $2.5 Discount Per Security: $0.175
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to US$2.90, the stock trades at a trailing P/E ratio of 8.5x. Average forward P/E is 16x in the Personal Products industry in the US.
お知らせ • Aug 16Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million.Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,275,510 Price\Range: $3.92
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: US$0.17 (vs US$0.087 in 2Q 2024)Second quarter 2025 results: EPS: US$0.17 (up from US$0.087 in 2Q 2024). Revenue: US$8.13m (up 1.4% from 2Q 2024). Net income: US$1.47m (up 125% from 2Q 2024). Profit margin: 18% (up from 8.2% in 2Q 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in the US.
Recent Insider Transactions • Aug 03CEO & Chairman recently bought US$80k worth of stockOn the 30th of July, Jack Ross bought around 28k shares on-market at roughly US$2.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jack has been a buyer over the last 12 months, purchasing a net total of US$2.9m worth in shares.
お知らせ • Aug 01Synergy CHC Corp. to Report Q2, 2025 Results on Aug 14, 2025Synergy CHC Corp. announced that they will report Q2, 2025 results Pre-Market on Aug 14, 2025
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$3.61, the stock trades at a trailing P/E ratio of 13.4x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 203% over the past year.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 33%After last week's 33% share price gain to US$3.24, the stock trades at a trailing P/E ratio of 12.1x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 4,850% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 27%After last week's 27% share price gain to US$2.65, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 3,949% over the past three years.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$2.07, the stock trades at a trailing P/E ratio of 7.7x. Average forward P/E is 23x in the Personal Products industry in the US. Total returns to shareholders of 3,063% over the past three years.
New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$16m). High level of non-cash earnings (83% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (7.2% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$17.7m market cap).
Reported Earnings • May 15First quarter 2025 earnings released: EPS: US$0.10 (vs US$0.077 in 1Q 2024)First quarter 2025 results: EPS: US$0.10 (up from US$0.077 in 1Q 2024). Revenue: US$8.17m (down 13% from 1Q 2024). Net income: US$876.3k (up 51% from 1Q 2024). Profit margin: 11% (up from 6.2% in 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Personal Products industry in the US.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$1.77, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 2,875% over the past three years.
お知らせ • May 02Synergy CHC Corp. to Report Q1, 2025 Results on May 15, 2025Synergy CHC Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025
お知らせ • Apr 19Synergy CHC Corp., Annual General Meeting, Jun 18, 2025Synergy CHC Corp., Annual General Meeting, Jun 18, 2025.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 40%After last week's 40% share price gain to US$2.50, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 16x in the Personal Products industry in the US. Total returns to shareholders of 6,903% over the past three years.
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$17m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.1% net profit margin). Market cap is less than US$100m (US$19.7m market cap).
Reported Earnings • Mar 31Full year 2024 earnings released: EPS: US$0.28 (vs US$0.84 in FY 2023)Full year 2024 results: EPS: US$0.28 (down from US$0.84 in FY 2023). Revenue: US$34.8m (down 19% from FY 2023). Net income: US$2.12m (down 67% from FY 2023). Profit margin: 6.1% (down from 15% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the US.
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Personal Products industry in the US. Total returns to shareholders of 12,589% over the past three years.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 21x in the Personal Products industry in the US. Total returns to shareholders of 22,971% over the past three years.
Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$4.15, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 26x in the Personal Products industry in the US. Total returns to shareholders of 31,604% over the past three years.
お知らせ • Nov 27Synergy CHC Corp. to Report Q3, 2024 Results on Dec 06, 2024Synergy CHC Corp. announced that they will report Q3, 2024 results Pre-Market on Dec 06, 2024
お知らせ • Oct 25Synergy CHC Corp. Common Stock Deleted from OTC EquitySynergy CHC Corp. Common Stock has been deleted from OTC Equity effective October 23, 2024, due to Market Center Change Listed on NASDAQ.
お知らせ • Oct 23Synergy CHC Corp. has completed an IPO in the amount of $10.35 million.Synergy CHC Corp. has completed an IPO in the amount of $10.35 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,150,000 Price\Range: $9 Discount Per Security: $0.63
お知らせ • Jun 28Synergy CHC Corp. has filed an IPO in the amount of $23 million.Synergy CHC Corp. has filed an IPO in the amount of $23 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: New Market Listing
お知らせ • Jul 18Synergy CHC Files Form 15Synergy CHC Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock, par value $0.00001 per share.
